CompletedPhase 1NCT02503774

MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.

The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination with MEDI4736 in Adult Participants with Select Advanced Solid Tumors

Checked against the public recordLast updated Jul 11, 2023 · Source: ClinicalTrials.gov

StatusCompleted
PhasePhase 1
U.S. locations18
SponsorMedImmune LLC
01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
MedImmune LLC
Interventions being studied
Drug: Oleclumab; Drug: Durvalumab
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach
03
Public criteria

Who may be able to participate

Inclusion Criteria: * Adult participants; age ≥ 18 * Written and signed informed consent must be obtained * Have histologic or cytologic documentation of solid tumor including EGFRm NSCLC * Participants must have at least 1 lesion that is measurable using RECIST guidelines * Participants must consent to provide archived tumor specimens or tumor biopsies for correlative biomarker studies. * Eastern Cooperative Oncology Group performance score of 0 or 1 * Adequate organ function Exclusion Criteria: * Prior treatment with tumor necrosis factor receptor superfamily agonists including OX40, CD27, CD137 (4-1BB), CD357 (GITR). One cohort also excludes anti CTLA-4, PD-L1, and anti PD-L1. * Participants who have received prior therapy with regimens containing CTLA-4, PD-L1, or PD-1 antagonists may be permitted to enroll under certain conditions * Cardiac or peripheral vascular disease meeting any of the following criteria: * Past history of myocardial infarction in the prior 12 months * Past history of stroke or transient ischemic attack requiring medical therapy * Congestive heart failure ≥ Class 3 based on New York Heart Association Functional Classification * Grade 3 or greater edema (eg, peripheral, pulmonary) * History of Grade 3 or greater thromboembolic events in the prior 12 months * Participants with active tuberculosis are ineligible. In settings where there is clinical or radiographic evidence of tuberculosis, active disease must be ruled out * Active or prior documented autoimmune or inflammatory disorders * Untreated central nervous system (CNS) metastatic disease * Known positive for human immunodeficiency virus (HIV), chronic or active hepatitis B or active hepatitis A or C * Other invasive malignancy within 2 years except for noninvasive malignancies such as cervical carcinoma in situ, in situ prostate cancer, non-melanomatous carcinoma of the skin, ductal carcinoma in situ of the breast that has been surgically cured * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, active peptic ulcer disease or gastritis, uncontrolled hypertension, uncontrolled diabetes, or psychiatric illness/social situations that would limit compliance with study requirement

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Research SiteLa Jolla, California
  • Research SiteNew Haven, Connecticut
  • Research SiteGainesville, Florida
  • Research SiteAtlanta, Georgia
  • Research SiteSt Louis, Missouri
  • Research SiteDurham, North Carolina
  • Research SiteCincinnati, Ohio
  • Research SiteColumbus, Ohio
  • Research SiteNashville, Tennessee
  • Research SiteDallas, Texas
  • Research SiteHouston, Texas
  • Research SiteCamperdown

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 11, 2023. Always confirm current availability with the study team.

View original record ↗